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General Information.  All reactions were perfomed using flame- or oven-dried glassware under
an atmosphere of dry nitrogen.  Commercial reagents were purified prior to use according to the
guidelines of Perrin and Armarego.1  Non-aqueous reagents were transferred under nitrogen by syringe.
Organic solutions were concentrated under reduced pressure using a Buchi rotary evaporator.  Methylene
choride and N,N-diisopropylethylamine were distilled from calcium hydride immediately prior to use.
Chlorobenzene was used as supplied by Acros.  (R,R)-1,2-bis(2-phenyloxazolin-4-yl)benzene was
prepared as described by Bolm and coworkers.2  Chromatographic purification of products was
accomplished using forced-flow chromatography on ICN 60 32-64 mesh silica gel 63 according to the
method of Still.3 Thin-layer chromatography (TLC) was performed on EM Reagents 0.25 mm silica gel
60-F plates.  Visualization of the developed chromatogram was performed by fluorescence quenching or
KMnO4 stain.
1H and 13C NMR spectra were recorded on Bruker DRX-500 (500 MHz and 125 MHz,
respectively), AMX-400 (400 MHz and 100 MHz), AMX-300 (300 MHz and 75 MHz), Varian I500 (500
MHz and 125 MHz), or Mercury 300 (300 MHz and 75 MHz) as noted, and are internally referenced to
residual protio solvent signals.  Data for 1H NMR are reported as follows: chemical shift (δ ppm),
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration, coupling constant
                                                 
1Perrin, D. D.; Armarego, W. L. F.  Purificaion of Laboratory Chemicals; 3rd ed., Pregamon Press, Oxford, 1988.
2
 Bolm, C.
J. Am. Chem. Soc. Supporting Information S2
(Hz) and assignment.  Data for 13C NMR are reported in terms of chemical shift.  IR spectra were
recorded on a Perkin-Elmer 1600 Series spectrometer using NaCl salt plates, and reported in terms of
frequency of absorption (cm-1). Mass spectra were obtained from the UC Irvine Mass Spectral Facility.
Optical rotations were recorded on a Jasco P-1010 polarimeter (WI lamp, 589 nm, 25°C).    Gas
chromatography was performed on Hewlett-Packard 5890A and 6890 Series gas chromatographs
equipped with a split-mode capillary injection system and flame ionization detectors using the following
columns: Bodman Chiraldex Γ-TA (30 m x 0.25 mm) and C&C Column Technologies CC-1701 (30 m x
0.25 mm). HPLC analysis was performed on a Hewlett-Packard 1100 Series HPLC at 254nm using the
following Chiralcel columns: OD-H (25 cm) and OD guard (5 cm), AD (25 cm) and AD guard (5 cm), OJ
(25 cm) and OJ guard (5 cm).
(R,R)-1,2-Dichloro-4,5-bis(2-phenyloxazolin-4-yl)benzene (ArCl2-PhBox 2b).  A solution of
4,5-dichloro-1,2-phthalonitrile (500 mg, 2.5 mmol), (R)-phenylglycinol (1.04 g, 7.6 mmol), and
anhydrous ZnCl2 (17 mg, 130 µmol) in chlorobenzene (9 mL ) was warmed to reflux for 12 h.  After
cooling to room temperature, the solvent was removed by rotary evaporation, and the residue was
partitioned between CH2Cl2 (15 mL) and water (15 mL ).  The organic phase was dried (Na2SO4),
concentrated, and purified by flash chromatography (66:33 hexanes:EtOAc) to afford 579 mg (1.32 mmol,
52% yield) of 2b as a viscous yellow oil.  IR (thin film) 3061, 3030, 2898, 1652, 1505, 1488, 1393, 1034
cm-1;  1H NMR (300 MHz, CDCl3) δ 7.26-7.33 (m, 10H, PhH), 6.07 (s, 2H, ClPhH), 5.32 (dd, J = 9.2, 9.2
Hz, 2H, OCH2CHN), 4.67 (dd, J = 8.5, 9.9 Hz, 2H, OCH 2CHN), 4.16 (dd, J = 8.2, 8.5 Hz, 2H,
OCH2CHN).  13C NMR (75 MHz, CDCl3) δ 149.5, 142.4, 128.8, 128.6, 127.7, 127.1, 110.5, 102.5, 75.5,
70.8; HRMS (FAB) exact mass calcd for (C24H18Cl2N2O2 + H+) requires m/z 437.0824, found m/z
437.0817.  [α]D = +68.1 (c = 1.0, CHCl3).
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(R,R)-1,2-Dichloro-4,5-bis(2-(p-methoxyphenyl)oxazolin-4-yl)benzene (ArCl2-PMPBox 2c).
(R)-(p-Methoxyphenyl)glycinol was prepared as previously described.4  A solution of 4,5-dichloro-1,2-
phthalonitrile (2.4 g, 12 mmol), (R)-(p-methoxyphenyl)glycinol (5.0 g, 30 mmol), and anhydrous ZnCl2
(160 mg, 1.2 mmol) in chlorobenzene (120 mL) was warmed to reflux for 7 h.  After cooling to room
temperature, the solvent was removed by rotary evaporation, and the residue was partitioned between
CH2Cl2 (15 mL) and H2O (15 mL ).  The organic phase was dried (Na2SO4), concentrated, and purified by
flash chromatography (66:33 to 50:50 hexanes:EtOAc gradient).  The resulting solid was recrystallized
from EtOAc and hexanes to give 4.0 g (8.0 mmol, 67%) of 2c a white crystalline material.  IR (thin film)
1955, 1906, 1833, 1669, 1649, 1514, 1247, 951, 832 cm-1;  1H NMR (300 MHz, CDCl3) δ 7.96 (s, 2H,
ClPhH), 7.24 (d, J = 8.8 Hz, 4H, MeOPhH), 6.82 (d, J = 8.8 Hz, 4H, MeOPhH), 5.30 (dd, J = 8.5, 9.9 Hz,
1H, OCH2CHN), 4.67 (dd, J = 8.5, 10.2 Hz, 2H, OCH(H)CHN), 4.18 (dd, J = 8.5, 8.5 Hz, 2H,
OCH(H)CHN), 3.78 (s, 6H, OCH3).  13C NMR (75 MHz, CDCl3) δ 162.6, 159.0, 134.9, 133.8, 131.8,
128.0, 127.9, 114.0, 75.6, 70.1, 55.3; HRMS (CI) exact mass calcd for (C26H22Cl2N2O4+) requires m/z
496.0957, found m/z 496.0956; [α]D = +72.9 (c = 1.0, CHCl3).
General Procedure.  To a flask charged with ArCl2-PMPBox 2c and anhydrous MgI2 in an inert
atmosphere, was added CH2Cl2 (4 mL) and the resulting pale yellow solution was stirred vigorously for 1
h under an inert atmosphere.  The allyl morpholine (0.4 mmol) was then added via syringe as a solution in
CH2Cl2 (1 mL ).  The syringe was rinsed with CH2Cl2 (3 x 1 mL), and the combined rinses were added to
the reaction flask.  The reaction mixture was then treated with i-Pr2NEt, then cooled to –20 °C.  At this
point, a solution of the acid chloride (1.0 M in CH2Cl2) was added over 12 h.  After a further 12 hours at
–20 °C, the reaction mixture was washed with a mixture of EtOAc (25 mL) and 1 N NaOH (25 mL).  The
layers were separated, and the aqueous layer was extracted with EtOAc (2 x 25 mL).  The combined
organic layers were then  washed with saturated aq. NaCl (50 mL), dried (Na2SO4), and then concentrated.
The resulting residue was then added to EtOH (15 mL) and set aside.  After 6-10 h, the precipitated
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ArCl2-PMPBox ligand was removed by filtration, and the resulting supernatant solution was concentrated
by rotary evaporation.  The resulting residue was then purified by preparative HPLC or by flash
chromatography.
(2S)-N-(2-Benzyloxy-4-pentenoyl)-morpholine (Table 1, Entry 6)  Prepared by the general
procedure from N-allyl morpholine (51 mg, 0.40 mmol) and benzyloxyacetyl chloride (0.48 mL, 1.0 M
solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c (398 mg, 0.80
mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 80% yield (88 mg,
0.32 mmol); 91% ee.  IR (thin film) 2916, 2854, 1643, 1457, 1436, 1114 cm-1;  1H NMR (400 MHz,
CDCl3) δ 7.27-7.37 (m, 5H, PhH), 5.83 (ddd, J = 7.0, 10.2, 17.1 Hz, 1H, CH=CH2), 5.10-5.17 (m, 2H,
CH=CH2), 4.62 (d, J = 11.7 Hz, 1H, CH2Ph), 4.45 (d, J = 11.7 Hz, 1H, CH2Ph), 6.54 (dd, J = 6.0, 8.0 Hz,
1H, CHOCH2Ph), 3.57-3.83 (m, 8H, N(CH2CH2)2), 2.47-2.62 (m, 2H, CH2CH=CH2); 13C NMR (100
MHz, CDCl3) δ 169.6, 137.3, 133.4, 128.5, 128.0, 128.0, 118.0, 79.0, 71.4, 67.1, 66.8, 45.7, 42.6, 36.7;
HRMS (CI) exact mass calcd for (C16H21NO3 + H+) requires m/z 276.1599, found m/z 276.1594; [α]D =
+30.2 (c = 1.0, CHCl3).
The enantiomeric purity was determined by HPLC with a Chiralcel OJ column and OJ guard
column (10% EtOH:hexanes, 1 mL/min flow); tr = 16.8 min and 19.3 min.
(2S)-N-(2-Methoxy-4-pentenoyl)-morpholine (Table 2, Entry 5)  Prepared by the general
procedure from N-allyl morpholine (51 mg, 0.40 mmol) and methoxyacetyl chloride (0.48 mL, 1.0 M
solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c (398 mg, 0.80
mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 28% yield (22 mg,
0.11 mmol); 80% ee.  IR (thin film) 2946, 2853, 2812, 1721, 1659, 1119 cm-1;  1H NMR (400 MHz,
CDCl3) δ 5.81 (ddd, J = 7.0, 10.2, 17.1 Hz, 1H, CH=CH2), 5.09-5.16 (m, 2H, CH=CH2), 4.07 (dd, J = 6.0,
7.8 Hz, 1H, CH OCH3), 3.64-3.78 (m, 8H, N(CH2CH2)2), 3.35 (s, 3H, CH 3), 2.44-2.55 (m, 2H,
CH2CH=CH2); 13C NMR (100 MHz, CDCl3) δ 169.5, 133.4, 117.9, 81.1, 67.1, 66.9, 56.9, 45.6, 42.6,
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36.4; HRMS (CI) exact mass calcd for (C10H17NO3+) requires m/z 199.1208, found m/z 199.1211; [α]D =
+2.1 (c = 1.0, CHCl3).
The enantiomeric purity was assayed by derivitization of a portion of the product to the
iodolactone (I2, 1:1 H2O:DME, 15 min) and analysis by GC with a Bodman Chiraldex Γ-TA column (50
°C, 1 °C/min gradient, 1 mL/min); minor diastereomer, tr = 92.9 min and 107.7 min.
(2S)-N-(2-Phenoxy-4-pentenoyl)-morpholine (Table 2, Entry 4)  Prepared by the general
procedure from N-allyl morpholine (51 mg, 0.40 mmol) and phenoxyacetyl chloride (0.48 mL, 1.0 M
solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c (398 mg, 0.80
mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 48% yield (50 mg,
0.19 mmol); 78% ee.  IR (thin film) 3072, 2968, 2916, 2854, 1643, 1597, 1228 cm-1;  1H NMR (400 MHz,
CDCl3) δ 7.25-7.29 (m, 2H, PhH), 6.96-7.00 (m, 1H, PhH), 6.89 (d, J = 8.8 Hz, 2H, PhH), 5.88 (ddd, J =
7.0, 10.0, 17.0 Hz, 1H, CH=CH2), 5.14-5.22 (m, 2H, CH=CH2), 4.85 (dd, J = 6.5, 7.5 Hz, 1H, CH2OPh),
3.36-3.78 (m, 8H, N(CH2CH2)2), 2.70-2.72 (m, 2H, CHCH=CH2); 13C NMR (100 MHz, CDCl3) δ 168.8,
157.2, 132.7, 129.8, 121.8, 118.5. 114.9, 78.5, 67.0, 66.7, 45.8, 42.9, 36.8; HRMS (CI) exact mass calcd
for (C15H19NO3 + H+) requires m/z 262.1443, found m/z 262.1438; [α]D = –26.3 (c = 1.0, CHCl3).  The
enantiomeric purity was determined by HPLC with a Chiralcel OJ column and OJ guard column (3%
EtOH:hexanes, 1 mL/min flow); tr  = 28.3 min and 32.6 min.
(2S)-N-(2-(p-Chlorophenoxy)-4-pentenoyl)-morpholine (Table 2, Entry 3)  Prepared by the
general procedure from N-allyl morpholine (51 mg, 0.40 mmol) and (p-chlorophenoxy)acetyl chloride
(0.48 mL, 1.0 M solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c
(398 mg, 0.80 mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 59%
yield (70 mg, 0.24 mmol); 71% ee.  IR (thin film) 3072, 2968, 2916, 2854, 1643, 1597, 1493, 1234 cm-1;
1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 9.0 Hz, 1H, PhH), 6.83 (d, J = 9.0 Hz, 1H, PhH), 5.87 (ddd, J
= 7.0, 10.0, 17.0 Hz, 1H, CH=CH2), 5.15-5.23 (m, 2H, CH=CH2), 4.80 (dd, J = 6.2, 7.5 Hz,, 1H, CH-
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O(PhCl)), 3.39-3.75 (m, 8H, N(CH2CH2)2), 2.68-2.76 (m, 2H, CHCH=CH2); 13C NMR (100 MHz,
CDCl3) δ 168.4, 155.8,  132.4, 129.7, 118.7, 116.2, 114.9, 78.9, 67.0, 66.7, 45.8, 42.9, 36.7; HRMS (CI)
exact mass calcd for (C15H18NO3Cl+) requires m/z 295.0975, found m/z 295.0969; [α]D = –17.7 (c = 1.0,
CHCl3).
The enantiomeric purity was determined by HPLC with a Chiralcel AD column and AD guard
column (3% i-PrOH:hexanes, 1 mL/min flow); tr = 36.2 min and 41.8 min.
(2S)-N-(2-Acetoxy-4-pentenoyl)-morpholine (Table 2, Entry 1)  Prepared by the general
procedure from N-allyl morpholine (51 mg, 0.40 mmol) and acetoxyacetyl chloride (0.48 mL, 1.0 M
solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c (398 mg, 0.80
mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 44% yield (40 mg,
0.18 mmol); 37% ee.  IR (thin film) 2968. 2926, 2864, 1737, 1654, 1451, 1239 cm-1;  1H NMR (400 MHz,
CDCl3) δ 5.74 (ddd, J = 7.1, 10.1, 17.1 Hz, 1H, CH=CH2), 5.29 (m, 1H, CHOAc), 5.11-5.13 (m, 2H,
CH=CH2), 3.48-3.69 (m, 8H, N(CH2CH2)2), 2.48-2.57 (m, 2H, CH2CH=CH2), 2.10 (s, 3H, OAc); ); 13C
NMR (100 MHz, CDCl3) δ 171.0, 168.2, 132.3, 119.3, 69.6, 67.2, 66.8, 46.4, 42.8, 36.0, 21.0; HRMS
(CI) exact mass calcd for (C11H17NO4+) requires m/z 227.1158, found m/z 257.1152; [α]D = –4.3 (c = 1.0,
CHCl3).
The enantiomeric purity was assayed by derivitization of a portion of the product to the
deprotected secondary alcohol (NaBH4, MeOH, 2 h) and analysis by GC with a Bodman Chiraldex Γ-TA
column (70 °C, 3 °C/min gradient, 1 mL/min); minor diastereomer, tr = 34.6 min and 35.9 min.
(2S)-N-(2-(t-Butyldimethylsilyloxy)-4-pentenoyl)-morpholine (Table 2, Entry 2)  Prepared by
the general procedure from N-allyl morpholine (51 mg, 0.40 mmol) and (t-butyldimethylsilyl)oxyacetyl
chloride (0.48 mL, 1.0 M solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-
PMPBox 2c (398 mg, 0.80 mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless
oil in 67% yield (81 mg, 0.27 mmol); 38% ee.  IR (thin film) 5/77, 2911, 2854, 1643, 1462, 1436, 1249,
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839 cm-1;  1H NMR (400 MHz, CDCl3) δ 5.75 (ddd, 7.0, 10.1, 17.2 Hz, 1H, CH=CH2), 5.06-5.10 (m, 2H,
CH=CH2), 4.38-4.45 (m, 1H, CH -OTBS), 3.56-3.85 (m, 8H, N(CH2CH2)2), 2.24-2.45 (m, 2H,
CH2CH=CH2), 0.86 (s, 9H, SiC(CH3)3), 0.04 (s, 4H, Si(CH3)2); 13C NMR (100 MHz, CDCl3) δ 171.1,
133.5, 118.1, 75.7, 67.1, 67.0, 45.9, 42.7, 39.9, 25.7, 18.1, -4.7, -5.2; HRMS (CI) exact mass calcd for
(C15H29NO3Si + H+) requires m/z 300.1995, found m/z 300.1986; [α]D = +6.2 (c = 1.0, CHCl3).
The enantiomeric purity was assayed by derivitization of a portion of the product to the
deprotected secondary alcohol (2N HCl, MeOH, 30 min) and analysis by GC with a Bodman Chiraldex Γ-
TA column (70 °C, 3 °C/min gradient, 1 mL/min); minor diastereomer, tr = 34.5 min and 35.8 min.
(2S)-N-(2-Benzyloxy-5-methyl-4-pentenoyl)-morpholine (Table 3, Entry 2) Prepared by the
general procedure from N-methallyl morpholine (57 mg, 0.40 mmol) and benzyloxyacetyl chloride (0.48
mL, 1.0 M solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80 mmol), ArCl2-PMPBox 2c (398
mg, 0.80 mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the product as a colorless oil in 78% yield
(90 mg, 0.31 mmol); 91% ee.  IR (thin film) 3072, 3030, 2968, 2916, 2854, 1643, 1457, 1436 cm-1;  1H
NMR (400 MHz, CDCl3) δ 7.21–7.34 (m, 5H, PhH), 4.83 (s, 1H, CMe=CH2), 4.77 (s, CMe=CH2), 4.60
(d, 1H, J = 11.6 Hz, 1H, CH2Ph), 4.43 (d, 1H, J = 11.6 Hz, 1H, CH2Ph), 4.33 (dd, J = 5.5, 8.7 Hz, 1H,
CHOCH2Ph), 3.56-3.75 (m, 8H, N(CH2CH2)2), 2.52 (dd, J = 8.7, 14.3 Hz, 1H, CH2CMe=CH2), 2.41 (dd,
J = 5.4, 14.3 Hz, 1H, CH2CMe=CH2); 13C NMR (100 MHz, CDCl3) δ 169.9, 141.1, 137.3, 128.5, 128.0,
128.0, 113.6, 78.5, 71.6, 67.1, 66.8, 45.7, 42.5, 40.6, 22.5; HRMS (CI) exact mass calcd for (C17H23NO3 +
H+) requires m/z 290.1756, found m/z 290.1764;  [α]D = +30.0 (c = 1.0, CHCl3).
The enantiomeric purity was determined by HPLC with a Chiralcel OJ column and OJ guard
column (6% i-PrOH:hexanes, 1 mL/min flow); tr = 14.8 min and 16.4 min.
(2S)-N-(2-Benzyloxy-5-phenyl-4-pentenoyl)-morpholine (Table 3, Entry 3)  Prepared by the
general procedure from N-(2-phenyl-2-propenyl)morpholine (81 mg, 0.40 mmol) and benzyloxyacetyl
chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol), ArCl2-PMPBox
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2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a colorless oil in 79%
yield (111 mg, 0.32 mmol);  90% ee.  IR (thin film) 3030, 1926, 1854, 1716, 1643, 1509, 1451, 1244 cm-
1;  1H NMR (300 MHz, CDCl3) δ 7.20-7.40 (m, 10H, PhH), 5.39 (d, J = 1.4 Hz, CPh=CH2), 5.20 (d, J =
1.1 Hz, CPh=CH2), 4.55 (d, J = 11.5 Hz, 1H, CH2Ph), 4.35 (d, J = 11.5 Hz, 1H, CH2Ph), 4.28 (dd, J = 6.9,
7.1 Hz, 1H, CHOCH2Ph), 3.42-3.63 (m, 8H, N(CH2CH2)2), 3.00 (dd, J = 0.8, 6.9 Hz, 2H, CH2CPh=CH2);
13C NMR (75 MHz, CDCl3) δ169.6, 143.5, 139.9, 137.1, 128.3, 128.2, 127.8, 127.6, 126.0, 115.8, 99.9,
77.0, 71.4, 67.0, 66.6, 45.6, 42.4, 38.5; HRMS (CI) exact mass calcd for (C22H25NO3 + H+) requires m/z
352.1912, found m/z 352.1912; [α]D = +4.9 (c = 1.0, CHCl3).
The enantiomeric purity was determined by HPLC with a Chiralcel AD column and AD guard
column (10% i-PrOH:hexanes, 1 mL/min flow); tr = 13.4 min and 16.0 min.
(2S,3R)-N-(2-Benzyloxy-3-(benzoyloxymethyl)-4-pentenoyl)-morpholine (Table 3, Entry 4)
Prepared by the general procedure from (E)-N-(4-benzoyloxy-2-butenyl)morpholine (105 mg, 0.40 mmol)
and benzyloxyacetyl chloride (0.48 mL, 1.0 M solution in CH2Cl2, 0.48 mmol), using MgI2 (222 mg, 0.80
mmol), ArCl2-PMPBox 2c (398 mg, 0.80 mmol), and i-Pr2NEt (0.11 mL, 0.60 mmol) to afford the
product as a colorless oil in 86% yield (140 mg, 0.34 mmol); syn:anti 92:8; 86% ee.  Syn isomer:  IR (thin
film) 3072, 3030, 2968, 2916, 2854, 1716, 1643, 1451, 1275 cm-1;  1H NMR (400 MHz, CDCl3) δ 7.94 (d,
J = 7.1 Hz, 2H, C(O)PhH), 7.53 (t, J = 7.4 Hz, 1H, C(O)PhH), 7.39 (dd, J = 7.9, 7.5 Hz, 2H, C(O)PhH),
7.18-7.28 (m, 5H, CH2(PhH)), 5.78 (ddd, J = 9.3, 10.2, 17.1 Hz, 1H, , CH=CH2), 5.15-5.21 (m, 2H,
CH=CH2), 4.65 (d, J = 11.7 Hz, 1H, CH2Ph), 4.49-4.51 (m, 2H, CH2OBz), 4.42 (d, J = 11.7 Hz, 1H,
CH2Ph), 4.27 (d, J = 9.5 Hz, 1H, CHOBn), 3.54-3.73 (m, 8H, N(CH2CH2)2), 2.91-2.96 (m, 1H, CH-
CH=CH2); 13C NMR (100 MHz, CDCl3) δ 168.6, 166.3, 136.8, 134.0, 133.0, 130.0, 129.6, 129.5, 128.5,
128.4, 128.2, 128.2, 120.3, 97.4, 72.3, 67.1, 66.7, 64.5, 46.7, 45.6, 42.6; HRMS (CI) exact mass calcd for
(C24H27NO5 + H+) requires m/z 410.1967, found m/z 410.1952; [α]D = +8.6 (c = 1.0, CHCl3).
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The enantiomeric purity and diastereomer ratio were determined by HPLC with a Chiralcel OD-H
column and OD guard column (10% i-PrOH:hexanes, 1 mL/min flow); syn isomer, tr = 20.1 min and 29.5
min; anti isomer, tr = 23.2 min and 26.0 min.
(2S,3S)-N-(2-Benzyloxy-3-(p-nitrophenyl)-4-pentenoyl)-morpholine (Table 3, Entry 5)
Prepared by the general procedure from (E)-N-(p-nitrocinnamyl)morpholine (99 mg, 0.40 mmol) and
benzyloxyacetyl chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol),
ArCl2-PMPBox 2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a
colorless oil in 82% yield (136 mg, 0.33 mmol);  syn:anti 99:1; syn 97% ee.  Syn isomer: IR (thin film)
3061, 2968, 2911, 2854, 1737, 1649, 1519, 1457, 1436, 1348, 1239 cm-1; 1H NMR (300 MHz, CDCl3) δ
8.14 (d, J = 8.8 Hz, 2H, (NO2)PhH), 7.35 (d, J = 8.8 Hz, 2H, (NO2)PhH), 7.21-7.25 (m, 3H, CH2PhH),
6.99 (d, J = 7.7 Hz, 2H, CH2PhH), 5.94 (ddd, J = 8.8, 10.4, 17.0 Hz, 1H, CH=CH2), 5.08-5.18 (m, 2H,
CH=CH2), 4.52 (d, J = 12.1 Hz, 1H, CH2Ph), 4.44 (d, J = 9.6 Hz, 1H, CHOBn), 4.27 (d, J = 11.8 Hz, 1H,
CH2Ph), 3.87 (dd, J = 9.1, 9.1 Hz, 1H, CH-CH=CH2), 3.51-3.76 (m, 8H, N(CH2CH2)2); 13C NMR (75
MHz, CDCl3) δ 168.0, 147.8, 146.6, 136.1, 135.1, 129.1, 128.3, 128.0, 127.8, 123.5, 118.7, 81.8, 72.0,
67.0, 66.6, 53.0, 45.6, 42.7; HRMS (CI) exact mass calcd for (C22H24N2O5 + H+) requires m/z 397.1763,
found m/z 397.1756; [α]D = +4.0 (c = 1.0, CHCl3).
The enantiomeric purity and diastereomer ratio were determined by HPLC with a Chiralcel AD
column and AD guard column (15% i-PrOH:hexanes, 1 mL/min flow); syn isomer, t = 16.7 min and t =
26.1 min; anti isomer, tr = 21.9 min and 29.5 min.
(2S,3S)-N-(2-Benzyloxy-3-(ethoxycarbonyl)-4-pentenoyl)-morpholine (Table 3, Entry 6)
Prepared by the general procedure from (E)-ethyl 4-morpholinocrotonate (74 mg, 0.40 mmol) and
benzyloxyacetyl chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol),
ArCl2-PMPBox 2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a
colorless oil in 84% yield (111 mg, 0.32 mmol);  syn:anti 97:3;  syn 96% ee.  Syn isomer:  IR (thin film)
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2968, 2916, 2864, 1737, 1649, 1457, 1441 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27-7.37 (m, 5H, PhH),
5.75 (ddd, J = 9.1, 10.1, 17.1 Hz, 1H, CH=CH2), 4.61 (d, J = 11.7 Hz, 1H, CH2Ph), 4.60 (d, J = 10.5 Hz,
1H, CH-OBn), 4.51 (d, J = 11.7 Hz, 1H, CH2Ph), 4.11-4.25 (m, 2H, OCH2CH3), 3.50-3.65 (m, 9H, CH-
CH=CH2), N(CH2CH2)2), 1.24 (t, J = 7.1 Hz, OCH2CH3); 13C NMR (100 MHz, CDCl3) δ 171.1, 167.6,
136.9, 130.7, 128.4, 128.1, 128.1, 120.6, 79.4, 72.3, 67.0, 66.7, 61.2, 54.0, 45.7, 42.5, 14.1; HRMS (CI)
exact mass calcd for (C19H25NO5 + H+) requires m/z 348.1811, found m/z 348.1804; [α]D = –31.8 (c = 1.0,
CHCl3).
The enantiomeric purity and diastereomer ratio were determined by HPLC with a Chiralcel AD
column and AD guard column (10% EtOH:hexanes, 1 mL/min flow); syn isomer, tr = 15.5 min and 20.6
min; anti isomer, tr = 14.1 min and 19.5 min.
(2S,3R)-N-(2-Benzyloxy-3-chloro-4-pentenoyl)-morpholine (Table 3, Entry 7)  Prepared by the
general procedure from (E)-N-(3-chloro-2-propenyl)morpholine (65 mg, 0.40 mmol) and benzyloxyacetyl
chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol), ArCl2-PMPBox
2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a colorless oil in 95%
yield (118 mg, 0.38 mmol); syn:anti 98:2; 91% ee.  1H NMR, 13C NMR, IR, and mass spectral data for
this compound were consistent with those previously reported.5  [α]D = –5.8 (c = 1.0, CHCl3). The
enantiomeric purity was determined by HPLC with a Chiralcel OJ column and OJ guard column (10%
EtOH:hexanes, 0.5 mL/min); syn isomer, t = 53.0 min and t = 61.5 min.  The diastereomer ratio was
determined by GC with a CC-1701 column (70 °C, 7 °C/min gradient, 1 mL/min); syn isomer, tr = 29.8
min, anti isomer, tr =30.3 min.
(2S,3S)-N-(2-Benzyloxy-3-chloro-4-pentenoyl)-morpholine (Table 3, Entry 8)  Prepared by the
general procedure from (Z)-N-(2-phenyl-2-propenyl)morpholine (81 mg, 0.40 mmol) and benzyloxyacetyl
chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol), ArCl2-PMPBox
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2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a colorless oil in 79%
yield (111 mg, 0.32 mmol). 1H NMR, 13C NMR, IR, and mass spectral data for this compound were
consistent with those previously reported.5  [α]D = +54.9 (c = 1.0, CHCl3).  The enantiomeric purity and
diastereomer ratio were determined by HPLC with a Chiralcel OJ column and OJ guard column (6%:1%
i-PrOH:EtOH:hexanes, 1 mL/min flow); anti isomer, tr = 37.6 min and 51.0 min; syn isomer, tr = 48.2
min.
(2S,3S)-N-(2-Benzyloxy-3-(ethoxycarbonyl)-3-methyl-4-pentenoyl)-morpholine (5).  Prepared
by the general procedure from ethyl (E)-4-morpholino-2-methylcrotonate (85 mg, 0.40 mmol) and
benzyloxyacetyl chloride (1.0 mL, 1.0 M solution in CH2Cl2, 1.0 mmol), using MgI2 (334 mg, 1.2 mmol),
ArCl2-PMPBox 2c (597 mg, 1.2 mmol), and i-Pr2NEt (0.21 mL, 1.2 mmol) to afford the product as a
colorless oil in 75% yield (109 mg, 0.30 mmol); syn:anti 94:6; syn 97% ee.  IR (thin film) 3093, 3051,
2968, 2906, 2854, 1732, 1654, 1457, 1441, 1239 cm-1;  1H NMR (300 MHz) δ 7.26-7.34 (m, 5H, Ph), 5.94
(dd, J = 10.7, 17.3 Hz, 1H, CH=CH2), 5.11-5.18 (m, 2H, CH=CH2), 4.76 (s, 1H, CHOBn), 4.59 (d, J =
11.8 Hz, CH2Ph), 4.43 (d, J = 11.8 Hz, CH 2Ph), 4.06-4.21 (m, 2H, OCH2CH3), 3.34-3.60 (m, 8H,
N(CH2CH2)2), 1.44 (s, 3H, CH3), 1.21 (t, J = 7.1 Hz, OCH2CH3); 13C NMR (75 MHz, CDCl3) δ 173.0,
167.2, 137.1, 136.8, 128.2, 127.9, 127.9, 116.3, 79.2, 72.5, 67.0, 66.4, 61.3, 53.9, 46.4, 42.4, 15.4, 14.1;
HRMS (CI) exact mass calcd for (C20H27NO5 + H+) requires m/z 362.1967, found m/z 362.1960; [α]D =
–33.6 (c = 1.0, CHCl3).
The enantiomeric purity and diastereomer ratio were determined by HPLC with a Chiralcel AD
column and AD guard column (6% i-PrOH:hexanes, 1 mL/min flow); syn isomer, tr = 15.7 min and 17.6
min; anti isomer, tr = 16.5 min.
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1. I2, 1:1 H2O:DME





Determination of the absolute configuration of (2S)-N-(2-benzyloxy-4-pentenoyl)-morpholine
by correlation with (2S)-2-benzyloxy-4-pentenoic acid methyl ester (S1).  A solution of (2S)-N-(2-
benzyloxy-4-pentenoyl)-morpholine (23 mg, 84 µmol) in 2 mL 1:1 water/ DME was placed in an 8 mL
scintillation vial equipped with a magnetic stir bar.  The solution was treated with iodine (53 mg, 0.21
mmol) and stirred at 23 °C for 10 min.  The reaction was then quenched with 10% aqueous Na2S2O3 (1
mL) and extracted into Et2O.  The resulting organic layer was dried (Na2SO4) and concentrated.  The
unpurified iodolactone product was then taken up in glacial AcOH (1 mL).  The resulting solution was
then treated with zinc dust (55 mg, 0.84 mmol) and stirred at 65 °C for 1.5 h.  Upon cooling to ambient
temperature, 1 N HCl (aq) (1 mL) was added, and the resulting mixture was extracted with Et2O (3 x 1
mL).  The organic extracts were combined, dried (Na2SO4), and concentrated.  The resulting carboxylic
acid was then taken up in MeOH and TMS-CHN2 (2.0 M in hexanes) was added dropwise until a bright
yellow color persisted.  The reaction was then treated with a drop of AcOH and concentrated.  The residue
was purified by flash chromatography (5:1 hexanes:EtOAc) to afford 9.5 mg (43 µmol, 52% yield) of a
clear oil that was spectroscopically identical in all respects to the compound (2S)-2-benzyloxy-4-

















H2, Pd/C H2, Pd/C
Determination of the absolute stereochemistry of (2S,3S)-N-(2-benzyloxy-3-chloro-4-
pentenoyl)-morpholine by correlation with (2S)-N-(2-hydroxypentanoyl)-morpholine (S1).  A
suspension containing (2S)-N-(2-benzyloxy-4-pentenoyl)-morpholine (19 mg, 68 µmol) of known
absolute configuration (vide supra) and 10% palladium on carbon (25 mg) in 1 mL ethanol was stirred
under an atmosphere of H2 for 30 min.  The catalyst was removed by filtration through a short plug of
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celite, and the filtrate was concentrated.  Purification of the residue by flash chromatography (1:1
hexanes:EtOAc) afforded 12 mg (68 µmol, 96% yield) of a colorless film. [α]D = + 4.0  (c = 1.0, CHCl3).
A suspension containing of (2S,3S)-N-(2-benzyloxy-3-chloro-4-pentenoyl)-morpholine (43 mg,
0.14 mmol) and 10% palladium on carbon (50 mg) in EtOH (2 mL) was stirred under at atmosphere of H2
for 1 h.  The catalyst was then removed by filtration through a short plug of celite, and the filtrate was
concentrated.  Purification of the residue by flash chromatography (1:1 hexanes:EtOAc) afforded 25.4 mg
(0.14 mmol, 97%)  of a colorless oil that was spectroscopically identical to S1 in all respects. [α]D = + 2.4













Determination of the absolute stereochemistry of (2S,3R)-N-(2-benzyloxy-3-chloro-4-
pentenoyl)-morpholine by correlation with (2S)-N-(2-hydroxypentanoyl)-morpholine (S2). A
suspension containing of (2S,3R)-N-(2-benzyloxy-3-chloro-4-pentenoyl)-morpholine (26.2 mg, 84.6
µmol) and 10% palladium on carbon (50 mg) in EtOH (2 mL) was stirred under at atmosphere of H2 for
1.5 h.  The catalyst was then removed by filtration through a short plug of celite, and the filtrate was
concentrated.  Purification of the residue by flash chromatography (1:1 hexanes:EtOAc) afforded 15 mg
















1. I2, 1:1 DME:H2O
2. Zn0, AcOH, 65 °C
1. H2, Pd/C
2. LiOH, H2O/THF
Determination of the absolute stereochemistry of (2S ,3S)-N-(2-benzyloxy-3-
(ethoxycarbonyl)-4-pentenoyl)-morpholine by correlation with (2S,3R)-3-ethylmalic acid. A solution
of (2S,3S)-N-(2-benzyloxy-3-(ethoxycarbonyl)-4-pentenoyl)-morpholine (34 mg, 0.1 mmol) in 2.4 mL 1:1
H2O/DME was treated with iodine (64 mg, 0.25 mmol) and stirred at 23 °C for 1 h.  The resulting solution
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was then treated with 10% aqueous Na2S2O3 (1 mL) and extracted into Et2O.  The resulting organic layer
was dried (Na2SO4) and concentrated.  The iodolactone residue was then taken up in glacial AcOH (2.5
mL) and treated with zinc dust (65 mg, 1.0 mmol) and stirred at 65 °C for 1.5 h.  Upon cooling to ambient
temperature, 1 N HCl (aq) (1 mL) was added, and the mixture was extracted with Et2O (3 x 1 mL).  The
organic extracts were combined, dried (Na2SO4), and then concentrated.
The resulting carboxylic acid was taken up in THF (4 mL) and treated with 10% palladium on
carbon (50 mg) and stirred under an H2 atmosphere for 1 h.  The catalyst was then removed by filtration
through a short plug of celite, and the filtrate was concentrated.  The resulting residue was then taken up
in 3:1 THF:H2O (4 mL) and treated with LiOH•H2O (42 mg, 1.0 mmol).  The solution was warmed to 65
°C for 14 h.  After cooling to ambient temperature, the reaction mixture was added to Dowex 50X80-200
(H+ form) resin.  The resin was removed by filtration and washed with H2O.  The combined filtrate was
concentrated to afford 7 mg of a yellow oil (43 µmol, 43% for 4 steps) that was identical to (2R,3S)-3-
ethylmalic acid7 in all regards except for optical rotation, which was opposite in sign. [α]D (literature) = -
3.1 (c = 1.0, H2O); [α]D (observed) = +1.4 (c = 1.0, H2O).
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